Key findings

Patients with immune-mediated inflammatory diseases do not have elevated thromboembolic risk when treated with JAK inhibitors, finds a meta-analysis conducted by Italian investigators and reported in the journal Rheumatology .

Background

Previous studies have linked JAK inhibitors to higher risk, prompting regulatory bodies such as the European Medicines ...